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ABSTRACT
Background:  Resection of colorectal liver metastasis (CRLM) can be curative. 
Predicting which patients may benefit from resection, however, remains challenging. 
Some microRNAs (miRNAs) become deregulated in cancers and contribute to cancer 
progression. We hypothesized that miRNA expression can serve as a prognostic 
marker of survival after CRLM resection.
Results: MiR-203 was significantly overexpressed in tumors of short-term 
survivors compared to long-term survivors. R1/R2 margin status and high clinical 
risk score (CRS) were also significantly associated with short-term survival (both  
p = 0.001). After adjusting for these variables, higher miR-203 expression remained 
an independent predictor of shorter survival (p = 0.010). In the serum cohort, high 
CRS and KRAS mutation were significantly associated with short-term survival  
(p = 0.005 and p = 0.026, respectively). After adjusting for CRS and KRAS status, 
short-term survivors were found to have significantly higher miR-203 levels (p = 0.016 
and p = 0.033, respectively).
Materials and Methods: We employed next-generation sequencing of small-
RNAs to profile miRNAs in solid tumors obtained from 38 patients who underwent 
hepatectomy for CRLM. To validate, quantitative reverse-transcription polymerase 
chain reaction (qRT-PCR) was performed on 91 tumor samples and 46 preoperative 
serum samples. 
Conclusions: After CRLM resection, short-term survivors exhibited significantly 
higher miR-203 levels relative to long-term survivors. MiR-203 may serve as a 
prognostic biomarker and its prognostic capacity warrants further investigation.
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INTRODUCTION
Colorectal cancer (CRC) is the third most prevalent 
cancer in both men and women in the U.S., and about 
half of all recurrences after CRC resection involve 
the liver [1, 2]. Resection of colorectal liver metastasis 
(CRLM) offers a chance of cure in 1 in 5 patients [3]. The 
challenge is determining which patients are likely to recur 
early and die of their disease or to have a long disease-
free interval or be cured. A prior study from Memorial 
Sloan Kettering Cancer Center (MSKCC) showed that 
median survival after resection for CRLM was roughly 42 
months among 1001 consecutive patients [4]. A clinical 
risk score (CRS) from 0–5 that predicted outcome after 
CRLM resection was created, in which 1 point was given 
for each of 5 clinical variables [4]. These variables were 
composed of node-positive primary, disease free interval 
from CRC resection to CRLM diagnosis of < 12 months, 
number of CRLM > 1, largest CRLM size > 5 cm, and 
carcinoembryonic antigen (CEA) > 200 ng/mL [4]. CRS 
of 0 predicted median survival of 74 months, whereas a 
CRS of 5 predicted median survival of only 22 months 
[4]. On subsequent analysis, however, the CRS loses its 
significance after patients survive for several years [5]. 
As the CRS demonstrates, identifying consistent 
and reliable predictors of outcome after CRLM resection 
remains a universal challenge. The ability of most models 
using clinicopathological data to predict outcome leads 
to concordance indices of approximately 0.6, which is 
not much better than chance alone [6]. Because of these 
deficiencies, scoring systems do not typically influence the 
treatment options provided.
In recent years, investigators have also studied the 
impact of BRAF or KRAS mutational status on patient 
outcomes after CRLM resection. Approximately 25% of 
CRLM resected patients were found to harbor the KRAS 
mutations at codon 12 and 13 and 2–4% were found 
to harbor the BRAF V600E mutation [7–12]. Patients 
harboring these mutations experienced worse survival after 
resection, potentially due to driving of drug resistance by 
such mutations [8–12]. However, our surgical experience 
revealed that many patients with wild type KRAS and 
BRAF also exhibited short-term survival after CRLM 
resection, despite lacking these unfavorable mutations. 
Identifying an additional reliable prognostic biomarker 
could optimize patient selection for liver resection with 
adjuvant regional and/or systemic chemotherapy and help 
determine the course of follow-up surveillance for CRLM 
recurrence. 
MicroRNAs (miRNA) are 19–25 nucleotide long 
post-transcriptional regulatory small non-coding RNAs 
which specifically downregulate target messenger RNA 
abundance and translation by binding to complementary 
sequences in the 3ʹ untranslated regions of transcripts 
[13]. Because of their critical roles in post-transcriptional 
regulation, aberrant expression of many miRNAs have 
been identified as critical in the multistep processes of 
cancer progression and metastasis either through their 
oncogenic or tumor suppressive functions [14–16]. CRC 
and CRLM have been associated with dysregulated 
expression of several miRNAs such as miR-145, miR-
221, miR-18a, and miR-27a [17–24]. Despite the growing 
knowledge of the prognostic potential of miRNAs as 
biomarkers in cancers in general and of their importance 
in regulating CRC and CRLM in particular, there is still 
a paucity of validated miRNAs that predict survival 
outcome in cancers [25–29]. The aim of this study was 
to profile differentially expressed miRNAs in tumors and 
preoperative sera in patients with short-term versus long-
term survival after CRLM resection. 
RESULTS
Available clinicopathological variables provide 
inconclusive prognostic power
A total of 91 patients in the tumor cohort and 46 
patients in the serum cohort who underwent initial CRLM 
resection were included in this study. In the tumor cohort, 
short-term survivors had a median overall survival of 
8.4 months. Long-term survivors had a median overall 
survival of 21 years with median follow-up of 16 years. 
In the serum cohort, short-term survivors had a median 
overall survival of 15 months. Long-term survivors had 
a median overall survival that has not yet been reached 
with a median follow-up of 5 years. Patient demographic 
and tumor characteristics for tumor and serum cohorts are 
shown in Table 1A and 1B, respectively. 
In the tumor cohort, CRC tumor node metastasis 
(TNM) stage, disease free interval (DFI) between CRC 
resection and CRLM diagnosis, largest CRLM tumor, 
CRLM margin status, and CRS were significantly different 
between short-term versus long-term survivors. When the 
CRS was stratified as low versus high risk, there was a 
significant difference between the two cohorts. However, 
of the 46 patients that were considered short-term 
survivors in the tumor cohort, 22 patients (48%) had a low 
risk CRS. Similarly, only 39 of 61 patients (64%) with a 
low CRS were long-term survivors. 
In the serum cohort, patients’ CRC TNM stage, 
CRLM synchronous or metachronous diagnosis, CRS, 
and KRAS mutation status were significantly different 
between short-term and long-term survivors. 48% of 
short-term survivors in the serum cohort harbored the 
KRAS mutation, compared to only 14% of the long-term 
survivors, which was significantly different (p = 0.037). 
Among these 15 KRAS mutants, 6 patients had mutations 
at G12D, 3 at G13D, 3 at G13V, 2 at G12C, and 1 at 
G13C. None of the 31 patients in the serum cohort tested 
for BRAF had a V600E mutation. 
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Table 1A: Patient demographic and tumor characteristics in the tumor cohort
Total
(n = 91)
Short-Term Survivors 
(n = 46)
Long-Term Survivors  
(n = 45)
p-value
Age 59 (28–83) 59 (28–83) 59 (28–79) 0.902
Male 57 (63) 30 (65) 27 (60) 0.668
CRC Location
     Colon
     Rectum
66 (73)
25 (27)
31 (67)
15 (33)
35 (78)
10 (22)
0.349
CRC Nodes
     Negative
     Positive
42 (46)
49 (54)
17 (37)
29 (63)
25 (56)
20 (44)
0.094
CRC TNM Stage at Presentation
     I
     II
     III
     IV
5 (5)
27 (30)
31 (34)
28 (31)
3 (7)
9 (20)
13 (28)
21 (46)
2 (4)
18 (40)
18 (40)
7 (16)
0.008
CEA
     < 200 ng/mL
     ≥ 200 ng/mL
76 (84)
9 (10)
37 (80)
6 (13)
39 (87)
3 (7)
0.483
Disease Free Interval
     < 12 months
     ≥ 12 months
44 (48)
47 (52)
29 (63)
17 (37)
15 (33)
30 (67)
0.006
CRLM Diagnosis
     Synchronous
     Metachronous
28 (31)
63 (69)
21 (46)
25 (54)
7 (16)
38 (84)
0.003
CRLM Largest Size 
     < 5 cm
     ≥ 5 cm
52 (57)
39 (43)
19 (41)
27 (59)
33 (73)
12 (27)
0.003
CRLM Numbers 
     Single
     Multiple
39 (43)
52 (57)
17 (37)
29 (63)
22 (49)
23 (51)
0.293
CRLM Differentiation
     Moderate
     Poor
57 (63)
8 (9)
34 (74)
3 (7)
23 (51)
5 (11)
0.275
CRLM Resectability
     R0
     R1
     R2
70 (77)
11 (12)
10 (11)
27 (59)
9 (20)
10 (22)
43 (96)
2 (4)
0 (0)
< 0.001
Clinical Risk Score
     0–2 Low Risk
     3–5 High Risk
61 (76)
30 (33)
22 (48)
24 (52)
39 (87)
6 (13)
< 0.001
Chemotherapy
     Pre-CRLM Resection
     Post-CRLM Resection
         Systemic only
         Systemic + HAIP
53 (58)
31 (34)
27 (30)
33 (72)
18 (39)
12 (26)
20 (44)
13 (29)
15 (33)
0.011
0.585
KRAS
   Mutant
   Wild type
10 (11)
10 (11)
8 (17)
4 (9)
2 (4)
6 (13)
0.170
BRAF V600E
   Mutant
   Wild type
0 (0)
18 (20)
0 (0)
12 (26)
0 (0)
6 (13)
−
Abbreviations: CRC, colorectal cancer; CRLM, colorectal liver metastasis; TNM, tumor node metastasis, CEA, 
carcinoembryonic antigen. HAIP, hepatic artery infusion pump.
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Table 1B: Patient demographic and tumor characteristics in the serum cohort
Total 
(n = 46)
Short-Term Survivors 
(n = 25)
Long-Term Survivors 
(n = 21)
p-value
Age 56 (26–78) 56 (26–78) 56 (36–73) 0.834
Male 31 (67) 17 (68) 14 (67) 1.000
CRC Location
     Colon
     Rectum
39 (85)
7 (15)
22 (88)
3 (12)
17 (81)
4 (19)
0.686
CRC Nodes
     Negative
     Positive
14 (30)
32 (70)
5 (20)
20 (80)
9 (43)
12 (57)
0.117
CRC TNM Stage at Presentation
     I
     II
     III
     IV
6 (13)
2 (4)
10 (22)
28 (61)
0 (0)
1 (4)
5 (20)
19 (76)
6 (29)
1 (5)
5 (24)
9 (43)
0.009
CEA
     < 200 ng/mL
     ≥ 200 ng/mL
40 (87)
4 (9)
20 (80)
4 (16)
20 (95)
0 (0)
0.114
Disease Free Interval
     < 12 months
     ≥ 12 months
36 (78)
10 (22)
21 (84)
4 (16)
15 (71)
6 (29)
0.475
CRLM Diagnosis
     Synchronous
     Metachronous
27 (59)
19 (41)
19 (76)
6 (24)
8 (38)
13 (62)
0.016
CRLM Largest Size 
     < 5 cm
     ≥ 5 cm
32 (70)
14 (30)
15 (60)
10 (40)
17 (81)
4 (19)
0.199
CRLM Numbers 
     Single
     Multiple
14 (30)
32 (70)
5 (20)
20 (80)
9 (43)
12 (57)
0.117
CRLM Differentiation
     Moderate
     Poor
37 (80)
4 (9)
18 (72)
4 (16)
19 (90)
0 (0)
0.111
CRLM Resectability
     R0
     R1
     R2
29 (63)
6 (13)
11 (24)
13 (52)
4 (16)
8 (32)
16 (76)
2 (10)
3 (14)
0.236
Clinical Risk Score
     0–2 Low Risk
     3–5 High Risk
18 (39)
28 (61)
5 (20)
20 (80)
13 (62)
8 (38)
0.006
Chemotherapy
     Pre-CRLM Resection
     Post-CRLM  Resection
         Systemic only
         Systemic + HAIP
 
36 (78) 
18 (39)
26 (57)
25 (100)
8 (32)
15 (60)
11 (52)
10 (48)
11 (52)
< 0.001
0.423
KRAS
     Mutant
     Wild Type
15 (33)
28 (61)
12 (48)
12 (48)
3 (14)
16 (76)
0.037
BRAF V600E
   Mutant
   Wild type
0 (0)
31 (67)
0 (0)
16 (64)
0 (0)
15 (71)
−
Abbreviations: CRC, colorectal cancer; CRLM, colorectal liver metastasis; TNM, tumor node metastasis, CEA, 
carcinoembryonic antigen. HAIP, hepatic artery infusion pump.
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Higher tumor miR-203 expression is associated 
with worse post-resection survival
Through unbiased small-RNA sequencing of human 
tumor RNAs, we identified miR-203 as a miRNA that is 
differentially expressed between the two survivor groups 
studied (Figure 1, log2Foldchange = 1.02, p-value = 0.006). 
Expression level of tumoral miR-203 was significantly 
increased among short-term survivors (Figure 2A, 
p = 0.006). To validate this finding, we re-measured miR-
203 in this group of 33 patients plus an additional cohort 
of 58 patients using qRT-PCR. In this expanded cohort of 
91 patients, we observed a significantly higher miR203 
expression in patients with poor prognosis (Figure 2B, 
p = 0.020, one-sided Wilcoxon rank sum test). 
Elevated serum miR-203 levels is associated with 
worse post-resection survival
To assess the potential of miR-203 as a minimally 
invasive biomarker, we obtained preoperative sera 
from an independent cohort of 46 patients with CRLM. 
Preoperative sera of short-term survivors contained 
significantly higher levels of miRNA-203 by qRT-PCR 
compared to long-term survivors (Figure 2C, p < 0.001). 
MiR-203 expression can be used as an 
independent prognostic biomarker
In univariate analyses as shown in Table 2A, 
lower miR-203 expression in CRLM tumor samples, 
as well as negative margin and low risk CRS were 
all significantly associated with long-term survival 
(p = 0.012, p = 0.001, p = < 0.001, respectively). 
After adjusting for margin status and CRS, lower 
expression of miR-203 remained significantly 
associated with long-term survival (OR = 0.52, 
p = 0.010). Moreover, the addition of information gained 
from miR-203 expression improved the concordance 
index, which was 0.776 based on margin status and 
CRS, to 0.843. 
Similarly, in the CRLM serum cohort, univariate 
analysis showed that low risk CRS and wild type KRAS 
were significantly associated with long-term survival 
(Table 2B and 2C, p = 0.005 and p = 0.026, respectively). 
After adjusting for CRS and KRAS status, miRNA-203 
differential expression in long-term survivors remained 
significant (Table 2B and 2C, p = 0.016 and p = 0.033, 
respectively). 
DISCUSSIONS
In this study, we identified miR-203 to be 
differentially regulated between short and long-term 
survivors after CRLM resection. This is important because 
prognostic markers can help optimize treatment plans. For 
example, patients with a small burden of disease but who 
are deemed high risk according to a prognostic marker may 
be offered chemotherapy trials instead of resection. This 
can allow for time to observe the progression of disease 
and to assess tumor chemosensitivity. The reverse is also 
true. A patient with small volume extrahepatic disease but 
who is deemed low risk may be offered a resection, which 
is usually not the standard treatment approach. 
The power of clinical risk scores is that they rely on 
data that is available prior to surgery and do not rely on 
factors such as response to treatment or comprehensive 
pathologic evaluation. These scores have been used to 
predict outcomes for patients with CRLM. While often 
significant in predicting disease-specific survival in single 
institution studies, some external validation attempts 
have failed to duplicate these findings [30]. This has led 
Figure 1: Next-generation sequencing of small-RNAs showed 16 miRNAs (squares and triangles) that were significantly 
differentially expressed, of which 10 miRNAs (triangles) exhibited an absolute fold change of 2 or above. MiR-203 
expression levels were significantly different between short-term vs. long-term survivors (log2Foldchange = 1.02, p = 0.006).
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investigators to search for additional prognostic factors. 
Preoperative serum levels of angiogenesis factors, for 
example, such as placenta growth factor (PIGF), combined 
with circulating tumor cell levels, have been identified as 
independent predictors of poor recurrence-free survival 
in a series of 107 patients [31]. There are also molecular 
risk scores that have been applied to patients with CRLM. 
Three separate tumor gene signatures have been developed 
at MSKCC to predict disease specific survival (19 genes), 
hepatic recurrence-free survival (115 genes), and overall 
survival (20 genes) [32, 33]. Up to 6 genes overlap among 
these gene signatures [32, 33]. The challenge in applying 
these molecular risk scores is that they require pathologic 
evaluation, which may require additional biopsies and 
testing of multiple genes, and often are comprised of 
genes that are not critical in metastasis. Given these 
limitations, this study was initiated to find miRNA as 
CRLM biomarkers.
Prognostic biomarkers reflect the intricate 
underlying biology that enables cancer cells to progress 
and cause worse patient outcome. Thus, the search for 
prognostic biomarkers parallels with much of the recent 
efforts to study metastatic mechanisms. The differential 
miRNA expression landscape among patients with varying 
stages of CRC including CRLM suggests that miRNA 
dysregulation is one of the mechanisms underlying multi-
step metastatic progression. For instance, our group 
recently showed that miRNA 483-5p and 551a were 
downregulated in metastatic CRC [15]. It was shown 
that both of these miRNAs shared a surprising metabolic 
target, CKB (Creatinine Kinase, Brain-type), which 
creates a reservoir of phosphocreatine for ATP generation 
that permits CRC cell survival during hepatic colonization 
where hypoxic stress impairs outgrowth [15]. In a study by 
another group, miRNA-99b-5p was shown to be expressed 
at higher levels in metastasis-free CRC patients relative 
to tumors of those who developed CRLM [25]. These 
studies suggested that deregulated miRNA expression both 
associates with and drives CRC progression.
The clinical importance of miR-203 in colorectal 
cancer has been poorly characterized until recently. MiR-
203 was found to be significantly higher in plasma of 
stage IV CRC patients compared to earlier staged CRC 
[27]. Another group also observed higher serum levels 
of miR-203 in CRLM compared to matched CRC, and 
showed that increased levels were associated with worse 
survival and metastasis to liver as well as lymph nodes, 
peritoneum, and distant organs [28]. This growing body of 
evidence implicated the important role of miR-203 level 
in regulating CRC progression. Our unbiased study also 
Table 2A: Tumor cohort logistic regression was performed with long-term survivorship as the 
outcome
Univariate Analysis Multivariate Analysis
OR 95% Lower 95% Upper p-value OR 95% Lower 95% Upper p-value
miRNA 0.617 0.424 0.897 0.012 0.517 0.314 0.851 0.010
Margin (R1/R2 vs R0) 0.066 0.014 0.307 0.001 0.066 0.013 0.344 0.001
Clinical risk score 
(high vs low) 0.141 0.050 0.397 < 0.001 0.169 0.052 0.555 0.003
Table 2B: Serum cohort logistic regression was performed with long-term survivorship as the 
outcome
Univariate Analysis Multivariate Analysis
OR 95% Lower 95% Upper p-value OR 95% Lower 95% Upper p-value
miRNA 0.527 0.324 0.859 0.010 0.506 0.292 0.879 0.016
Clinical risk score 
(high vs low) 0.154 0.041 0.575 0.005 0.102 0.019 0.537 0.007
Table 2C: Serum cohort logistic regression was performed with long-term survivorship as the 
outcome
Univariate Analysis Multivariate Analysis
OR 95% Lower 95% Upper p-value OR 95% Lower 95% Upper p-value
miRNA 0.527 0.324 0.859 0.010 0.568 0.338 0.954 0.033
KRAS (mutant vs 
wild type 0.188 0.043 0.815 0.026 0.177 0.035 0.883 0.035
Oncotarget18827www.impactjournals.com/oncotarget
implicated miR-203 in CRC pathogenesis. Specifically, 
this was the first study showing miR-203 differential 
expression to be associated with survivorship after CRLM 
resection. Importantly, the concordance index for the CRS 
and margin status was higher when miR-203 expression 
level was added. It is possible that miR-203, after study 
in a larger cohort, will enhance our ability to personalize 
treatment plans by capturing the appropriate level of risk 
associated with a patient’s CRLM.
Relative expressions and biological roles of 
miRNA-203 in CRC and CRLM remain to be elucidated. 
MiR-203 expression was shown to be upregulated in both 
CRC and CRLM compared to normal colon mucosa and 
implicated in epithelial to mesenchymal transition [34]. 
Another group reported that miRNA-203 was observed to be 
downregulated in both CRC and CRC cell lines compared 
to normal colon mucosa, and that lower expression was 
associated with larger CRC tumor and more advanced stage 
tumors [35]. Even though potential downstream targets 
of miR-203 were not included in the scope of this study, 
there have been several reports that suggest a wide scope 
of potential candidate targets whose levels are modulated 
by miR-203. One report implicated miR-203 as a negative 
regulator of ZNF 217 [36]. In lung cancer cells, miR-203 
was found to promote apoptosis through targeting SRC 
[37]. PIK3CA was also shown to be a direct target of miR-
203, whose downregulation was found to increase AKT 
signaling in gastric cancer [38]. MiR-203 is also predicted 
to target the 3’UTR of several genes for which aberrant 
expression levels have been associated with tumorigenesis 
and metastasis, such as PTP4A, PRKCB, and RAB10 [39]. 
These studies in aggregate suggest both cancer promoting 
and suppressive potential for miR-203 in CRC depending 
on the context. Our findings support a role for miR-203 in 
promoting colorectal cancer metastatic relapse. Needless to 
say, the causal role of miR-203 in the initiation, promotion, 
and relapse of CRLM remain to be investigated.
In addition to CRC and CRLM, miRNA-203 
expression was found to be deregulated in various 
cancer types, which may potentially reflect the tissue 
specific nature of miRNA-203. MiR-203 was shown to 
be down-regulated in melanoma [40], hepatocellular 
carcinoma [41], and cholangiocarcinoma [42]. On the 
other hand, miRNA-203 was overexpressed in pancreatic 
adenocarcinoma [43], prostate cancer [44], ovarian 
cancers [45], and metastatic breast cancer [46].
Figure 2: (A) Absolute expression level of miR-203 from next-generation sequencing analysis of 38 fresh frozen tumors 
demonstrated a significant upregulation of miR-203 among short-term survivors (p = 0.006). (B) Relative expression level of 
miR-203 from qRT-PCR of 91 tumor samples showed that short-term survivors exhibited significantly higher expression of miRNA-203 
compared to long-term survivors (p = 0.020, one-sided Wilcoxon rank sum test). (C) Relative expression level of miR-203 from qRT-PCR 
of 46 serum samples showed that short-term survivors exhibited significantly higher expression of miRNA-203 compared to long-term 
survivors (p < 0.001).
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In conclusion, short-term survivors after CRLM 
resection exhibit significantly higher miR-203 expression 
in their CRLM tissues and preoperative sera compared to 
long-term survivors. Curative intent of surgical resection 
can be further strengthened by prognostic factors including 
CRS, mutational status, and miR-203 expression. The 
prospect of knowing in advance the likelihood of survival 
in patients after CRLM surgery provides physicians 
with invaluable information for counseling patients and 
developing an optimal treatment plan. These studies 
warrant further large-scale studies to develop an approach 
to stratify patients according to their miR-203 status and 
additional molecular factors.
MATERIALS AND METHODS
Study population
With approval of the Institutional Review Board at 
MSKCC, specimens from 150 patients who underwent 
liver resection for CRLM from 1990 to 2014 were 
collected. Samples from 100 patients were used in the 
tumor cohort, and samples from an additional 50 patients 
were used in the serum cohort.
In the tumor cohort, 50 short-term survivors 
and 50 long-term survivors were selected. Short-term 
survivors were defined in the tumor cohort as patients who 
died of metastatic disease within 2.5 years after resection, 
whereas long-term survivors were patients who survived 
5 years beyond resection. These time points were selected 
to allow for adequate sample size and because patients 
with unresectable liver metastases treated with modern 
chemotherapy regimens survive on average between 
2 and 2.5 years [47, 48]. Five patients were excluded 
due to poor tissue miRNA quality and 4 patients were 
excluded for having had prior hepatectomy for CRLM. 
Thus, final analysis was based on 91 patients whose 
tumoral miRNAs were extracted after first occurrence 
of CRLM. We performed next-generation small-RNA 
sequencing on fresh frozen tumors from 38 patients. 
To validate the findings from the next-generation, qRT-
PCR was performed on 33 of the 38 original patients 
for whom we had adequate fresh frozen tumors plus 
an additional 58 patients for whom we had available 
formalin-fixed, paraffin embedded (FFPE) tissue slides 
for RNA extraction. In total, the tumor cohort consisted of 
91 patients whose tumoral miRNA expression levels were 
quantified and normalized by qRT-PCR.
In the serum cohort, 25 short-term survivors and 
25 long-term survivors were selected with preoperative 
sera obtained within 5 weeks of CRLM resection (median 
of 7 days; range 0–33 days). Four patients were excluded 
due to poor sample miRNA quality. Thus, the final analysis 
was based on 46 patients whose serum miRNAs were 
extracted and quantified by qRT-PCR. A new group of 
patients were selected for the serum cohort because most 
patients in the tumor cohort lacked preoperative serum 
collection for research. 
Patient information including demographic and 
relevant clinicopathological variables were obtained from 
a retrospective review. Preoperative laboratory results as 
well as details of the primary CRC and CRLM resection 
and pathology, KRAS and BRAF mutation status, 
subsequent recurrence, last follow up, and death were 
recorded. Clinical risk scores (CRS) were calculated for 
each patient as previously described by Fong et al, and 
it was further stratified as low risk (0–2) versus high risk 
(3–5) [4]. 
RNA extraction
From MSKCC’s prospectively maintained tissue 
bank, fresh frozen tumors or formalin fixed, paraffin 
embedded (FFPE) tissues mounted on glass slides were 
obtained for each patient. Solid tumor samples were flash 
frozen, preserved in RNAlater (Thermofisher AM7024) to 
minimize RNA degradation, cut and measured to roughly 
the same size, and grounded with disposable pestles (Sigma 
Z359947) before being subjected to RNA extraction 
using the Norgen miRNA purification kit (21300) per 
manufacturer’s instructions. Extracted RNA was then 
bioanalyzed for integrity prior to library preparation. To 
extract RNA from FFPE tissue slides, a pathologist (J.S.) 
reviewed the H&E slides for visual confirmation of tumor 
cells, and areas containing tumor cells were encircled for 
extraction. Tumor cells were scraped from corresponding 
unstained slides with a surgical blade, and miRNAs were 
isolated as described above. For the serum cohort, RNA 
was extracted from 1mL of serum using Norgen Plasma/
Serum Circulating and Exosomal RNA Purification Kit 
(Slurry Format) (42800). 
Next-generation sequencing
High-integrity RNA was used to perform small-
RNA library prepartion with NEXTflex™ Small RNA-
Seq Kit v2 per manufacturer’s instructions. The barcoded 
library was then bioanalyzed for quality and sequenced 
on an Illumina Hiseq 2000 at the Rockefeller University’s 
Genomic Resource Center. For analysis, we first performed 
quality trimming and linker removal (cutadapt v1.8). We 
then used bowtie2 to align the reads to the human genome 
miRNA database (hg19). Unmapped reads were then 
filtered using samtools (v1.3) and resulting miRNA read 
counts were analyzed for differential expression with the 
R package DEseq2 (Bioconductor).
Quantitative reverse-transcription PCR (qRT-
PCR)
Reverse transcription was performed using 
the Thermofisher TaqMan Reverse Transcription kit 
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(4366597). Subsequent quantitative PCR was performed 
using the Thermofisher Taqman hsa-miR-203 assay 
(00050) with hsa-miR-331 assay (Thermofisher A25576) 
as an endogenous control to derive ΔCt values (changes 
in threshold cycle). Relative miRNA-203 expression 
levels were derived using 2^(-ΔΔCt) method, where ΔΔCt 
was calculated by subtracting the average ΔCt value in 
long-term survivors from individual ΔCt values for each 
sample. MiR-331 was used as a control for all samples 
given that miR-331 was found to not be significantly 
different between two survival groups on the initial high-
throughput small-RNA sequencing. 
Statistical analysis
Continuous variables were presented using the 
median, whereas categorical variables were presented 
using frequency and percentage. Wilcoxon rank sum test 
and Fisher’s exact test were used to compare continuous 
and categorical variables, respectively, between long-term 
and short-term survivors. Univariate and multivariate 
logistic regressions were performed with long-term 
survivorship as the outcome. P-values < 0.05 were 
considered significant, and were derived from two-sided 
tests unless otherwise noted. All statistical analyses were 
performed using R version 3.2.2 (cran.r-project.org) and 
scatter plots were generated using GraphPad Prism V6.0 
(GraphPad Software, CA).
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